Springworks Therapeutics Inc (SWTX) Live Share Price, Invest From India

Springworks Therapeutics Inc Stock Performance

as on July 1, 2025 at 6:59 am IST

Day's High
$47.00
Day's Price Range
$47.01
$47.00
0.02%
Upside
52 Week's Low
52 Week's High
$32.83
52-Week Price Range
$47.02
$47.00
30.15%
Downside
0.04%
Upside

Springworks Therapeutics Inc share price movements today

Previous Close: $46.98
Open: $47.01
Volume: 1.2K
Day's Low - High: $47.00 - $47.01
52 Week Low - High: $32.83 - $47.02

Springworks Therapeutics Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Springworks Therapeutics Inc Stock Fundamentals & Key Indicators

Check Springworks Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

0.00%

Springworks Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Springworks Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Springworks Therapeutics Inc	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Springworks Therapeutics Inc Stock

Based on 15 analysts

BUY

93.33%

Buy

6.67%

Hold

0.00%

Sell

Based on 15 analysts, 93.33% of analysts recommend a 'BUY' rating for Springworks Therapeutics Inc. Average target price of $47

Springworks Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Springworks Therapeutics Inc.

Target Price

$47

Current Price

$47

Analyzed by

15 Analysts

Target

$47.00

Springworks Therapeutics Inc target price $47, a slight upside of 0% compared to current price of $47. According to 15 analysts rating.

Springworks Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	5	5	5	5	5	21	59	49	61	49
Gross Profit	5	5	4	4	4	19	57	45	55	45
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-69	-69	-77	-79	-94	-87	-39	-53	-77	-83
Net Profit Margin	-1205.41%	-1244.21%	-1337.08%	-1422.07%	-1731.63%	-416.00%	-66.83%	-108.58%	-125.59%	-169.47%

Springworks Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2009	Dec 2010	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	32	45	-	-	35	35	6	5	191
Gross Profit	16	22	0	0	34	0	6	5	179
Operating Income	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-
Net Income	5	10	-17	-54	-44	-173	-274	-325	-258
Net Profit Margin	17.64%	22.50%	0.00%	0.00%	-126.41%	-494.89%	-4460.06%	-5968.50%	-134.73%

Global Institutional Holdings in Springworks Therapeutics Inc

Funds	Holdings
FMR Inc	14.87%
Vanguard Group Inc	9.4%
BlackRock Inc	8.29%
State Street Corp	3.87%
T. Rowe Price Associates, Inc.	3.43%

See all

About Springworks Therapeutics Inc

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.

Organisation	Springworks Therapeutics Inc
E-voting on shares	Click here to vote

FAQs

What is Springworks Therapeutics Inc share price today?

Springworks Therapeutics Inc share price today is $47 as on July 1, 2025 at 1:29 am IST at the close of the market. Springworks Therapeutics Inc share today touched a day high of $47.01 and a low of $47.

What is the 52 week high and 52 week low for Springworks Therapeutics Inc share?

Springworks Therapeutics Inc share touched a 52 week high of $47.02 on June 20, 2025 and a 52 week low of $32.83 on April 9, 2025. Springworks Therapeutics Inc stock price today i.e. July 1, 2025 at 1:29 am IST is closed at $47,which is 0.04% down from its 52 week high and 43.16% up from its 52 week low.

How to invest in Springworks Therapeutics Inc Stock (SWTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Springworks Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Springworks Therapeutics Inc Shares that will get you 0.0319 shares as per Springworks Therapeutics Inc share price of $47 per share as on July 1, 2025 at 1:29 am IST.

What is the minimum amount required to buy Springworks Therapeutics Inc Stock (SWTX) from India?

Indian investors can start investing in Springworks Therapeutics Inc (SWTX) shares with as little as ₹94.702 or $1 (as of March 31, 2026 at 7:34 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹947.02 in Springworks Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on March 31, 2026 at 7:34 am IST). Based on Springworks Therapeutics Inc share’s latest price of $47 as on July 1, 2025 at 1:29 am IST, you will get 0.2128 shares of Springworks Therapeutics Inc. Learn more about fractional shares .